Pathology and Laboratory Medicine - part 2 pps

... Chem 20 01;47:464–470.84. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and riskof coronary artery disease. JAMA 20 01 ;28 6 :21 36 21 42. 32 Aroney and de Lemos 12. Haverkate ... Project. Stroke 20 00;31:18 02 1811. 24 . Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascular-ization for cardiogenic shock. JAMA 20 01 ;28 5:190–1 92. 25 . TIMI IIIB ... Sub-cutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. (see comments).N Engl J Med 1997;337:447–4 52. 29 . Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322 :33– 42. 30....

... heart dis-ease: prospective study and updated meta-analyses. Br Med J 20 00; 321 :199 20 4. 12. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reac-tive protein ... 1987;1:15 27 . 23 . Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensi-tivity c-reactive protein and lipid screening. Clin Chem 20 01;47 :28 –30. 24 . Köenig W. C-reactive ... ref-erence limit of serum C-reactive protein concentration. J Rheumatol 20 00 ;27 :23 51 23 59. 27 . Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation ofparticle-enhanced...

... 28 6CHECKMATE, 25 3CURE, 21 Disability Angina Pectoris Study,445ECAT, 29 2, 29 4, 445ESCALAT, 78ESSENCE, 22 , 40, 25 2EUROCARDI, 326 – 327 , 330FRISC, 9, 22 , 27 , 40, 46–47, 50, 23 8, 25 2, 29 5, 29 8FRAXIS, 22 GUARANTEE, ... 339–346Lp(a), 306malondialdehyde-modified LDL, 24 8, 25 0, 339–346myoglobin, 66–69, 75, 20 4, 21 8, 22 3, 22 4, 23 7, 26 5, 26 8, 27 1reperfusion success, 68–74standardization, 21 3 21 4with Chest Pain Unit ... 9,15argatroban, 24 dalteparin, 41, 25 2enoxoparin, 41, 25 3heparin, unfractionated (UFH), 20 , 21 , 24 26 , 28 , 47, 49, 52, 300hirudin, 24 hirulog, 24 inogatran, 24 low-molecular-weight heparin(LMWH), 17, 21 ,...

... infarc-tion: prognostic value of short- and long-term outcome and predictor of infarct size. AmHeart J 20 00;140: 126 –133.1 02. De Sutter J, Van de Wiele C, Gheeraert P, et al. The Selvester 3 2- point ... against doxoru-bicin toxicity. J Pharmacol Exp Ther 20 00 ;29 1 :29 9–3 02. 35. Al-Shabanah OA, Badary OA, Al-Gharably NM, Al-Sawaf HA. Effects of L-histidinol onthe antitumour activity and acute cardiotoxicity ... Cini-Neri G, Bandinelli M, Pacini P, Bartalucci S, Ciapini A. Doxorubicin and epi-rubicin cardiotoxicity: experimental and clinical aspects. Int J Clin Pharmacol Ther Toxicol1989 ;22 :21 7 22 1.61....

... resuscitation and cardioversion bymeans of combined thallium -2 0 1/technetium-99m pyrophosphate tomography. Eur J NuclMed 1995 ;22 : 128 6– 129 1.50. Grubb NR, Fox KA, Cawood P. Resuscitation from out-of-hospital ... under-standing of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113 :22 7 24 2.83. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and ... challenges. Curr Opin Mol Ther 20 00 ;2: 643–650.73. Rohlff C. Proteomics in molecular medicine: applications in central nervous systems dis-orders. Electrophoresis 20 00 ;21 : 122 7– 123 4.74. Jain KK. Applications...

... Markers 23 7Intraindividual biological variance, dI 2 = dtotal-W 2 - dA 2 Interindividual biological variance, dG = dtotal-B 2 - dA 2 - dI 2 where dtotal-W = total within-subject ... troponin T assay. J Am Coll Cardiol 20 00;1 02( Suppl II): 522 . 22 . Wu AHB, Apple FS. Reporting of cardiac troponin concentration [letter]. Clin Chem 20 02; 48 :20 77 20 82. 23 . Apple FS, Wu AHB, Jaffe AS. ... artery dis-ease and the acute coronary syndromes (Part 1). N Engl J Med 19 92; 326 :24 2 25 0.10. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery dis-ease and the...